Analyst Consensus ?
ConsensusBuy13 ratings
Bullish1184.6%
Neutral215.4%
Bearish00.0%
STERIS plc · STE · FY2027 Q2 · Calendar Q4 2026
STERIS raises FY2027 EPS outlook after 9% revenue growth
The quarter strengthens the growth case: revenue rose across segments and management lifted adjusted EPS guidance. However, some margin support came from one-time tariff refunds, while AST inventory dynamics and healthcare capital spending remain execution variables.
Why did STE rise 2.5% after beating EPS estimates in FY2027 Q2?
Research this report with FN2. Free to start; review your question before sending.
Reported After market closeNYSEHealthcare
$24.78B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.94
Consensus $2.68
EPS surprise
+9.7%
Reported versus consensus
Reported revenue
$1.60B
Consensus $1.56B
Revenue surprise
+2.4%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+2.5%
Event window
SPY move
-4.4%
Same window
Abnormal move
+6.9%
Stock minus SPY
Volume
2.3×
Versus trailing sessions
Subsequent drift
-1.1%
Up to 20 sessions
STESPY benchmark
Ask FN2 about STE FY2027 Q2
Choose a question to continue your research
Why did STE rise 2.5% after beating EPS estimates in FY2027 Q2?What changed in STE's guidance and outlook in FY2027 Q2?Give me the bull and bear case for STE after FY2027 Q2 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with the prior quarter's maintained outlook, management raised FY2027 adjusted EPS guidance while leaving the revenue outlook unchanged. The quarter also featured revenue growth across segments, a large Life Sciences capital-equipment order, the pending Xodus Medical acquisition, and a new restructuring plan.
Guidance delta
Management raised FY2027 adjusted EPS guidance and kept the revenue outlook unchanged. The prior quarter's outlook had been maintained.
Key takeaways
- Revenue grew 9% year over year, with margin expansion supported in part by tariff refunds.
- Adjusted EPS guidance increased; the revenue outlook was unchanged.
- Life Sciences capital-equipment sales surged, supported by onshoring and a large order.
- The pending Xodus Medical acquisition would expand the OR product line and consumables offering; a restructuring plan targets annual savings.
Management priorities
- Close and integrate the Xodus Medical acquisition.
- Execute restructuring and portfolio streamlining to pursue cost savings.
- Continue onshoring Life Sciences manufacturing and investing in R&D and high-margin consumables.
- Maintain capex to support growth while monitoring inventory levels.
Follow STE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$251.03Current
$245Low
$264.75Average
$275High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 6, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Aug 7, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 7, 2026 |
| Keybanc | Overweight | Overweight | Maintain | May 13, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 8, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | May 16, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | May 15, 2025 |
| Needham | Hold | Hold | Maintain | Apr 7, 2025 |
| Baird | Outperform | Outperform | Maintain | Aug 11, 2021 |
| Sidoti & Co. | Buy | Buy | Maintain | Nov 25, 2020 |
| Raymond James | Outperform | Strong Buy | Downgrade | Nov 25, 2020 |
| Griffin Securities | Hold | Buy | Downgrade | Nov 25, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 25, 2020 |
| B of A Securities | Buy | Buy | Maintain | Mar 15, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $251.03. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Patrick Wood | $275 | $218.4 | +9.5% | Jul 28, 2026 |
| Piper Sandler | Jason Bednar | $270 | $216.18 | +7.6% | May 21, 2026 |
| KeyBanc | Brett Fishbin | $269 | $210.85 | +7.2% | May 13, 2026 |
| Piper Sandler | Jason Bednar | $260 | $221.15 | +3.6% | Oct 24, 2024 |
| KeyBanc | Brett Fishbin | $265 | $241.1 | +5.6% | Sep 3, 2024 |
| Piper Sandler | Jason Bednar | $225 | $225.94 | -10.4% | May 10, 2024 |
| Wolfe Research | Mike Polark | $245 | $216.65 | -2.4% | Apr 4, 2024 |
Track every rating change on STE the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSTERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
Historical context
All STE earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| GMAB Genmab A/S | FY2026 Q3 · Calendar Q4 2026 | +55.6% | -4.3% | Genmab pairs nine-month growth with a heavier launch agenda |
| NTRA Natera, Inc. | FY2026 Q3 · Calendar Q4 2026 | -49.3% | -15.2% | Natera raises 2026 revenue outlook as Signatera drives Q3 growth |
| BDX Becton, Dickinson and Company | FY2026 Q4 · Calendar Q4 2026 | +2.0% | +2.1% | BD FY2026: Broad Growth, With FY2027 Margin and Alaris Risks |
| SOLV Solventum Corporation | FY2026 Q3 · Calendar Q4 2026 | +8.2% | -2.4% | Solventum lifts outlook after ERP cutover and Q3 execution |
| GH Guardant Health, Inc. | FY2026 Q3 · Calendar Q4 2026 | +61.3% | -9.0% | Guardant Health raises 2026 outlook as Shield growth accelerates |
| VTRS Viatris Inc. | FY2026 Q3 · Calendar Q4 2026 | +11.5% | -1.3% | Viatris raises 2026 outlook as complex generics and patches drive growth |
Latest beats and misses
Who reports nextBeat on EPS
- GMABFY2026 Q3 · November 5, 2026+55.6% EPS-4.3% move
- IRMFY2026 Q3 · November 5, 2026+4.6% EPS-11.1% move
- AFRMFY2027 Q1 · November 5, 2026+23.8% EPS+1.9% move
- VRSKFY2026 Q3 · November 5, 2026+2.1% EPS+6.9% move
- APDFY2026 Q4 · November 5, 20260.0% EPS-2.9% move
- ABNBFY2026 Q3 · November 5, 2026+10.9% EPS-3.5% move
Missed on EPS
- VMRKFY2026 Q3 · November 4, 2026-425.6% EPS+2.4% move
- NTRAFY2026 Q3 · November 5, 2026-49.3% EPS-15.2% move
- TIGOFY2026 Q3 · November 5, 2026-40.8% EPS+2.6% move
- UHALFY2027 Q2 · November 4, 2026-15.4% EPS-3.2% move
- LAMRFY2026 Q3 · November 5, 2026-3.6% EPS-0.8% move
- CMIFY2026 Q3 · November 5, 2026-6.0% EPS-4.9% move
Get the STE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-05T17:12:12.530899+00:00
- FN2 earnings calendar · 2026-11-06T01:23:16.275024+00:00
- Polygon adjusted daily market bars · 2026-11-06T15:50:46.240297+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-06T15:50:46.237526+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-06. For educational purposes only; not investment advice.